BR0307772A - Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência - Google Patents

Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência

Info

Publication number
BR0307772A
BR0307772A BR0307772-1A BR0307772A BR0307772A BR 0307772 A BR0307772 A BR 0307772A BR 0307772 A BR0307772 A BR 0307772A BR 0307772 A BR0307772 A BR 0307772A
Authority
BR
Brazil
Prior art keywords
treatment
incontinence
cyclooxygenase inhibitors
antimuscarinic agents
cyclooxygenase
Prior art date
Application number
BR0307772-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Ebrahim Versi
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0307772A publication Critical patent/BR0307772A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0307772-1A 2002-02-19 2003-02-14 Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência BR0307772A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35788802P 2002-02-19 2002-02-19
PCT/US2003/004561 WO2003070233A1 (en) 2002-02-19 2003-02-14 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence

Publications (1)

Publication Number Publication Date
BR0307772A true BR0307772A (pt) 2004-12-07

Family

ID=27757670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307772-1A BR0307772A (pt) 2002-02-19 2003-02-14 Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência

Country Status (12)

Country Link
US (1) US20030191172A1 (enExample)
EP (1) EP1476146A1 (enExample)
JP (1) JP2005526040A (enExample)
KR (1) KR20050005410A (enExample)
CN (1) CN1633283A (enExample)
AU (1) AU2003211078A1 (enExample)
BR (1) BR0307772A (enExample)
CA (1) CA2475374A1 (enExample)
MX (1) MXPA04008037A (enExample)
PL (1) PL372395A1 (enExample)
WO (1) WO2003070233A1 (enExample)
ZA (1) ZA200406148B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
EP1652523A4 (en) * 2003-08-04 2008-11-19 Kyorin Seiyaku Kk TRANSDERMALES ABSORPTION PREPARATION
CZ23088U1 (cs) * 2004-03-25 2011-12-19 Astellas Pharma Inc. Kompozice pevného farmaceutického prípravku solifenacinu nebo jeho soli
JP4895819B2 (ja) * 2004-10-29 2012-03-14 大鵬薬品工業株式会社 プロピベリン含有経口粉粒状製剤及びその製造法
WO2006082888A1 (ja) * 2005-02-03 2006-08-10 Kyorin Pharmaceutical Co., Ltd. 経皮吸収型製剤
WO2006090759A1 (ja) * 2005-02-25 2006-08-31 Astellas Pharma Inc. ソリフェナシン含有医薬
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
HRP20110634T1 (hr) * 2006-12-22 2011-10-31 Recordati Ireland Limited KOMBINIRANA TERAPIJA LIGANADA α<SUB>2</SUB>δ I NSAID ZA POREMEĆAJE DONJEG URINARNOG TRAKTA
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US8236857B2 (en) 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20120237574A1 (en) * 2010-07-08 2012-09-20 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10105330B2 (en) 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
EP2612660B1 (en) * 2012-01-04 2020-03-04 Wellesley Pharmaceuticals, LLC Extended-release formulation for reducing the frequency of urination and method of use thereof
TWI587879B (zh) * 2012-01-04 2017-06-21 魏斯理製藥公司 用於減少排尿頻率的延長釋放製劑及其使用方法
WO2013103389A1 (en) * 2012-01-04 2013-07-11 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
EP2612662B1 (en) * 2012-01-04 2020-03-04 Wellesley Pharmaceuticals, LLC Delayed-release formulation for reducing the frequency of urination and method of use thereof
CN103191429A (zh) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 用于缓解尿频的延长释放制剂及其使用方法
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
CN103191430A (zh) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 用于缓解尿频的缓释制剂及其使用方法
MX2014008283A (es) * 2012-01-04 2015-03-03 Wellesley Pharmaceutical Llc Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
EP2612663A1 (en) * 2012-01-04 2013-07-10 Wellesley Pharmaceuticals, LLC Extended-release formulation for reducing the frequency of urination and method of use thereof
CN107157991A (zh) * 2012-03-19 2017-09-15 韦尔斯利医药有限公司 用于缓解尿频的延长释放制剂及其使用方法
WO2014018223A1 (en) * 2012-07-27 2014-01-30 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
CN106714805A (zh) * 2014-06-06 2017-05-24 韦尔斯利医药有限公司 降低排尿频率的药物制剂及其使用方法
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
JP7195067B2 (ja) * 2018-06-20 2022-12-23 花王株式会社 ロズマリン酸誘導体又はその塩
JP2020033272A (ja) * 2018-08-27 2020-03-05 花王株式会社 過活動膀胱の予防又は改善剤
JP7223477B2 (ja) * 2018-10-10 2023-02-16 花王株式会社 Ｔｒｐｖ４活性抑制剤
CN110279863B (zh) * 2019-07-29 2022-02-22 牡丹江医学院 用于治疗泌尿疾病的药物组合物及其制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
IT1288123B1 (it) * 1996-09-04 1998-09-10 Nicox Sa Uso di nitroderivati per l'incontinenza urinaria
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
AU2001286557A1 (en) * 2000-08-23 2002-03-04 Merck Frosst Canada And Co. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria

Also Published As

Publication number Publication date
KR20050005410A (ko) 2005-01-13
WO2003070233A1 (en) 2003-08-28
EP1476146A1 (en) 2004-11-17
US20030191172A1 (en) 2003-10-09
PL372395A1 (en) 2005-07-25
CA2475374A1 (en) 2003-08-28
MXPA04008037A (es) 2004-11-26
JP2005526040A (ja) 2005-09-02
AU2003211078A1 (en) 2003-09-09
ZA200406148B (en) 2006-05-31
CN1633283A (zh) 2005-06-29

Similar Documents

Publication Publication Date Title
BR0307772A (pt) Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência
IL158559A0 (en) Acne treatment
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BRPI0308663B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
WO2005048942A3 (en) Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
BR9612661A (pt) Utilização de uma combinaç i de tensoatives agentes quelantes e óleos essenciais para desinfecção eficaz
EP1880719A3 (en) Composition for prophylaxis or treatment of urinary system infection and method thereof
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
BR9812342A (pt) Analgésica, método de tratar efetivamente a dor em humanos ou outros mamìferos, método para reduzir uma quantidade de opióide requerida para tratamento de pacientes afetados por dor e método para reduzir uma quantidade inibidor cox-2 requerida para tratamento de pacientes afetados por dor
BR9911666A (pt) Combinação farmacêutica, uso da combinação, processo para tratamento de uma doença inflamatória em uma pessoa sofrendo de ou susceptìvel a tal doença, e, composição farmacêutica
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
EP2377528A3 (en) Fatty acid metabolism inhibitors for use in the treatment of cancer
BR0108514A (pt) Uso de inibidores de il-18
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
BR0104282A (pt) Agente de barreira para um artigo absorvente, e, artigo absorvente
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BR0112212A (pt) Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes
BR0214810A (pt) Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação
BR0312768A (pt) Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos
BRPI0408491A (pt) tratamento da doença de alzheimer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.